GlaxoSmithKline ( ($GB:GSK) ) has issued an announcement. GSK announced that the European Medicine Agency’s Committee for ...

GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. Study Overview: GlaxoSmithKline (GSK) is conducting a Phase 3 ...

Part of a pharmaceutical factory which opened more than 75 years ago will be demolished. GSK plc (formerly GlaxoSmithKline) ...

The plans, lodged by pharmaceutical giant GSK plc (formerly GlaxoSmithKline), asked permission to destroy a single manufacturing building along with several associated tanks, pipe bridges, cooling ...

CNW/ - Dalhousie University, in collaboration with Nova Scotia Health's INSPIRED COPD Outreach Program, the Nova Scotia ...

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasisScynexis will promptly wind-down and terminate the MARIO ...

The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 3.1% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today at ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...